Hsiang-Chi Chen
A5059074411- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
Royal Marsden NHS Foundation Trust
2023-2024
Royal Marsden Hospital
2023
Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease (MRD) is emerging as a biomarker predict recurrence in patients with curatively treated early stage colorectal cancer (CRC). ctDNA risk stratifies guide adjuvant treatment decisions. We are conducting the UK’s first multi-centre, prospective, randomised study determine whether de-escalation strategy using chemotherapy (ACT) decisions non-inferior standard of care (SOC) chemotherapy, measured by 3-year free...
Abstract Purpose: The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection. Experimental Design: TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal plasma collection ctDNA occurred pre-...
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Sensitivity analysis for landmark and longitudinal populations (n=33)</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...
<p>TRACC B INVESTIGATORS</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>TRACC B INVESTIGATORS</p>
<p>Venn diagrams of ctDNA detection by call method according to analysis population</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<p>Genotypic and epigenetic considerations</p>
<p>ctDNA detection rate at baseline and postoperative timepoints according to stage in the primary analysis population (n=143)</p>
<p>Bioinformatics review of patients with ctDNA detected no recurrence or death from CRC</p>
<div>AbstractPurpose:<p>The absence of postoperative circulating tumor DNA (ctDNA) identifies patients with resected colorectal cancer (CRC) low recurrence risk for adjuvant chemotherapy (ACT) de-escalation. Our study presents the largest CRC cohort to date tissue-free minimal residual disease (MRD) detection.</p>Experimental Design:<p>TRACC (tracking mutations in cell-free predict relapse early cancer) included stage I III resectable CRC. Prospective longitudinal...
<p>Genotypic and epigenetic considerations</p>
<p>Sensitivity analysis for landmark and longitudinal populations (n=33)</p>
169 Background: Absence of post-operative ctDNA identifies resected CRC pts with low recurrence risk for potential adjuvant chemotherapy (ACT) de-escalation. We present the largest cohort plasma-only MRD detection, facilitating fast turnaround times, rapid treatment decisions and circumventing need tissue analysis, a challenge in real world practice. Methods: TRACC included stage I-III resectable CRC. Prospective longitudinal plasma collection occurred pre- post-surgery, after completion...